

# Craig Roberts

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9815306/publications.pdf>

Version: 2024-02-01

32  
papers

1,100  
citations

394421

19  
h-index

414414

32  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1701  
citing authors

#	ARTICLE	IF	CITATIONS
1	Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1943-1951.	3.3	24
2	Planning for monitoring the introduction and effectiveness of new vaccines using real-world data and geospatial visualization: An example using rotavirus vaccines with potential application to SARS-CoV-2. <i>Vaccine: X</i> , 2021, 7, 100084.	2.1	5
3	Impact of reduced human papillomavirus vaccination coverage rates due to COVID-19 in the United States: A model based analysis. <i>Vaccine</i> , 2021, 39, 2731-2735.	3.8	69
4	Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines. <i>Vaccine</i> , 2021, 39, 6727-6734.	3.8	5
5	Assessing the burden of pneumonia using administrative data from Malaysia, Indonesia, and the Philippines. <i>International Journal of Infectious Diseases</i> , 2016, 49, 87-93.	3.3	34
6	Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 403-416.	3.3	31
7	The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China. <i>BMC Infectious Diseases</i> , 2015, 15, 284.	2.9	22
8	Initial Medication Adherence—Review and Recommendations for Good Practices in Outcomes Research: An ISPOR Medication Adherence and Persistence Special Interest Group Report. <i>Value in Health</i> , 2015, 18, 690-699.	0.3	46
9	Comorbid risk, respondent characteristics and likelihood of pneumococcal vaccination versus no vaccination among older adults in Brazil. <i>Expert Review of Vaccines</i> , 2014, 13, 175-184.	4.4	4
10	Pneumococcal vaccine targeting strategy for older adults: Customized risk profiling. <i>Vaccine</i> , 2014, 32, 990-995.	3.8	2
11	A Systematic Literature Review of Psychosocial and Behavioral Factors Associated with Initial Medication Adherence: A Report of the ISPOR Medication Adherence & Persistence Special Interest Group. <i>Value in Health</i> , 2013, 16, 891-900.	0.3	78
12	Morbidity and mortality of pneumonia in adults in six Latin American countries. <i>International Journal of Infectious Diseases</i> , 2013, 17, e673-e677.	3.3	30
13	Reply to: Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. <i>Vaccine</i> , 2013, 31, 439-441.	3.8	2
14	Clinical and Economic Burden of Community-Acquired Pneumonia among Adults in the Czech Republic, Hungary, Poland and Slovakia. <i>PLoS ONE</i> , 2013, 8, e71375.	2.5	48
15	Response to “Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries”. <i>Vaccine</i> , 2011, 29, 7589-7590.	3.8	7
16	The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs*. <i>International Journal of Clinical Practice</i> , 2010, 64, 169-181.	1.7	44
17	Adherence to Aldosterone-Blocking Agents in Patients with Heart Failure. <i>American Journal of Therapeutics</i> , 2010, 17, 446-454.	0.9	11
18	Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. <i>BMC Cardiovascular Disorders</i> , 2010, 10, 29.	1.7	38

#	ARTICLE	IF	CITATIONS
19	Predicted Coronary Heart Disease Risk Reduction and Dual Blood Pressure/Cholesterol Goal Attainment in Patients With Hypertension Treated in Real-World Clinical Practice. <i>Journal of Clinical Hypertension</i> , 2010, 12, 396-406.	2.0	3
20	The Modeled Lifetime Cost-Effectiveness of Published Adherence-Improving Interventions for Antihypertensive and Lipid-Lowering Medications. <i>Value in Health</i> , 2010, 13, 685-694.	0.3	31
21	Barriers to adherence and hypertension control in a racially diverse representative sample of elderly primary care patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 672-681.	1.9	85
22	A multi-centre comparison of nursing staff time required for the preparation and administration of liposomal amphotericin B and amphotericin B deoxycholate vs. voriconazole. <i>Journal of Clinical Nursing</i> , 2009, 18, 1168-1179.	3.0	1
23	Economic Evaluation of Atorvastatin for Prevention of Recurrent Stroke Based on the SPARCL Trial. <i>Value in Health</i> , 2009, 12, 880-887.	0.3	14
24	Cost-Effectiveness of Atorvastatin in the Primary Prevention of Major Cardiovascular Events in Patients with Type 2 Diabetes in Canada. <i>Canadian Journal of Diabetes</i> , 2009, 33, 363-374.	0.8	2
25	The Impact of Concordant and Discordant Conditions on the Quality of Care for Hyperlipidemia. <i>Journal of General Internal Medicine</i> , 2008, 23, 1208-1213.	2.6	39
26	Economic Evaluation of Voriconazole for the Treatment of Candidemia in Canadian Adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2008, 19, 219-226.	1.9	10
27	Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. <i>Transplant Infectious Disease</i> , 2007, 9, 182-188.	1.7	25
28	Inhaled corticosteroids vs leukotriene receptor antagonists: health care costs across varying asthma severities. <i>Annals of Allergy, Asthma and Immunology</i> , 2006, 97, 236-243.	1.0	8
29	A systematic review and meta-analysis of misuse of antibiotic therapies in the community. <i>International Journal of Antimicrobial Agents</i> , 2005, 26, 106-113.	2.5	209
30	Rates and characteristics of intensive care unit admissions and intubations among asthma-related hospitalizations. <i>Annals of Allergy, Asthma and Immunology</i> , 2004, 93, 29-35.	1.0	106
31	Incremental effectiveness of amlodipine besylate in the treatment of hypertension with single and multiple medication regimens. <i>American Journal of Hypertension</i> , 2004, 17, 676-683.	2.0	19
32	Treatment Patterns in the Months Prior to and After Asthma-Related Emergency Department Visit. <i>Chest</i> , 2004, 126, 75-80.	0.8	48